# Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy

> **NCT07167446** · EARLY_PHASE1 · RECRUITING · sponsor: **Fox Chase Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients
- Metastatic Colorectal Cancer (CRC)
- Peripheral Neuropathy Due to Chemotherapy

## Interventions

- **DRUG:** Cannabidiol (CBD)
- **DRUG:** oxaliplatin-based chemotherapy

## Key facts

- **NCT ID:** NCT07167446
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-14
- **Primary completion:** 2027-09-05
- **Final completion:** 2028-09-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-10-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07167446

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07167446, "Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07167446. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*